Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Liabilities and Shareholders Equity (2016 - 2025)

Historic Liabilities and Shareholders Equity for Champions Oncology (CSBR) over the last 15 years, with Q4 2025 value amounting to $30.2 million.

  • Champions Oncology's Liabilities and Shareholders Equity rose 1950.08% to $30.2 million in Q4 2025 from the same period last year, while for Oct 2025 it was $123.7 million, marking a year-over-year increase of 1996.95%. This contributed to the annual value of $32.3 million for FY2025, which is 2377.16% up from last year.
  • Per Champions Oncology's latest filing, its Liabilities and Shareholders Equity stood at $30.2 million for Q4 2025, which was up 1950.08% from $30.5 million recorded in Q3 2025.
  • In the past 5 years, Champions Oncology's Liabilities and Shareholders Equity ranged from a high of $36.4 million in Q4 2022 and a low of $24.9 million during Q3 2024
  • Its 5-year average for Liabilities and Shareholders Equity is $30.3 million, with a median of $30.0 million in 2023.
  • Its Liabilities and Shareholders Equity has fluctuated over the past 5 years, first surged by 6756.22% in 2021, then crashed by 2590.25% in 2024.
  • Over the past 5 years, Champions Oncology's Liabilities and Shareholders Equity (Quarter) stood at $29.3 million in 2021, then rose by 24.13% to $36.4 million in 2022, then fell by 22.19% to $28.3 million in 2023, then decreased by 10.79% to $25.2 million in 2024, then grew by 19.5% to $30.2 million in 2025.
  • Its last three reported values are $30.2 million in Q4 2025, $30.5 million for Q3 2025, and $32.3 million during Q2 2025.